CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 21.7% in November

CytomX Therapeutics, Inc. (NASDAQ:CTMX) was the recipient of a large decline in short interest in November. As of November 15th, there was short interest totalling 4,440,000 shares, a decline of 21.7% from the October 31st total of 5,670,000 shares. Based on an average trading volume of 809,100 shares, the short-interest ratio is presently 5.5 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “neutral” rating on shares of CytomX Therapeutics in a report on Monday, November 11th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $5.77.

CytomX Therapeutics Stock Performance

CytomX Therapeutics stock opened at $1.06 on Friday. The stock has a market cap of $82.96 million, a PE ratio of 6.24 and a beta of 1.06. The stock has a 50-day moving average of $1.06 and a two-hundred day moving average of $1.28. CytomX Therapeutics has a one year low of $0.83 and a one year high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The company had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $18.92 million. During the same period last year, the business earned $0.04 EPS. As a group, sell-side analysts predict that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Institutional Investors Weigh In On CytomX Therapeutics

Large investors have recently made changes to their positions in the stock. US Bancorp DE acquired a new stake in CytomX Therapeutics during the 3rd quarter worth about $40,000. XTX Topco Ltd raised its stake in shares of CytomX Therapeutics by 382.6% in the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 48,033 shares during the last quarter. Forefront Analytics LLC raised its stake in shares of CytomX Therapeutics by 206.7% in the second quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 43,176 shares during the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of CytomX Therapeutics by 96.6% during the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 40,309 shares during the period. Finally, Virtu Financial LLC purchased a new stake in CytomX Therapeutics in the third quarter valued at approximately $104,000. 67.77% of the stock is owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.